Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 14/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504026 | 0.88 | HDAC3 (0.63) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL5507121 | 0.87 | ALDH1A1 (0.52) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5507110 | 0.79 | P2RY12 (0.59) | — | |
| SCHEMBL12933023 | 0.78 | HDAC3 (0.58) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL5503694 | 0.78 | ALDH1A1 (0.40) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL12932997 | 0.76 | L3MBTL1 (0.61) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL5525151 | 0.75 | GAA (0.60) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL12143948 | 0.75 | HDAC1 (0.65) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL7467929 | 0.75 | ALDH1A1 (0.77) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL12684570 | 0.74 | HDAC3 (0.59) | HDAC6HDAC3HDAC1HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108603-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108603-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-03 | — | — | US | disclosed |
| US-8114999-B2 | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-8114999-B2 | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100048588-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2010-02-25 | — | — | US | disclosed |
| US-20100048588-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2010-02-25 | — | — | US | disclosed |
| US-7501417-B2 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501417-B2 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC6 6/4885HDAC3 3/4885HDAC1 1/4885 |
| US-20100048588-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | HDAC6 13/4885HDAC3 2/4885HDAC1 1/4885 |
| US-20120108603-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | HDAC6 13/4885HDAC3 2/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.